| 000 | 01650 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250516061244.0 | ||
| 264 | 0 | _c20130221 | |
| 008 | 201302s 0 0 eng d | ||
| 022 | _a1533-2500 | ||
| 024 | 7 |
_a10.1111/j.1533-2500.2011.00515.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNavarro, Ana | |
| 245 | 0 | 0 |
_aCosts and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis. _h[electronic resource] |
| 260 |
_bPain practice : the official journal of World Institute of Pain _cJun 2012 |
||
| 300 |
_a382-93 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAmines _xeconomics |
| 650 | 0 | 4 |
_aAnalgesics _xeconomics |
| 650 | 0 | 4 |
_aCyclohexanecarboxylic Acids _xeconomics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGabapentin |
| 650 | 0 | 4 |
_aHealth Care Costs _xtrends |
| 650 | 0 | 4 |
_aHealth Resources _xeconomics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeuralgia _xdrug therapy |
| 650 | 0 | 4 | _aPregabalin |
| 650 | 0 | 4 |
_aSpain _xepidemiology |
| 650 | 0 | 4 |
_agamma-Aminobutyric Acid _xanalogs & derivatives |
| 700 | 1 | _aSaldaña, María T | |
| 700 | 1 | _aPérez, Concepción | |
| 700 | 1 | _aMasramón, Xavier | |
| 700 | 1 | _aRejas, Javier | |
| 773 | 0 |
_tPain practice : the official journal of World Institute of Pain _gvol. 12 _gno. 5 _gp. 382-93 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1533-2500.2011.00515.x _zAvailable from publisher's website |
| 999 |
_c21237095 _d21237095 |
||